Physician profile
Christopher Marshall
NPI 1982670360
$572.93
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $91.30 · 2021: $13.18.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $170.83 | 2019-2020 | |
| Lilly USA, LLC | $82.27 | 2019-2020 | |
| Glaxosmithkline, LLC. | $60.93 | 2019 | |
| Merck Sharp & Dohme LLC | $53.92 | 2019 | |
| Pfizer INC. | $48.78 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.30 | 2019 | |
| Csl Behring | $25.39 | 2019 | |
| Sanofi-Aventis U.S. LLC | $25.30 | 2019 | |
| Gilead Sciences, INC. | $14.68 | 2019 | |
| Shire North American Group INC | $13.61 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.18 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.05 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.39 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $11.30 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.